Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
[Shengxin Case] Issue 281: A Case Report on Nivolumab Treatment for Right Lower Gingival Squamous Cell Carcinoma
View details
→
[Happy Life Case] Issue 280: Nilotinib Treatment for Stage IVA Nasopharyngeal Carcinoma
[Case Study] Issue 279: A Case Sharing on Nilotinib Treatment for Nasopharyngeal Cancer
[Case Study] Issue 278: Nilotinib Treatment for Recurrent Cholangiocarcinoma
[XinSheng Academic] A prospective Phase II study of EGFR monoclonal antibody combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma resistant to induction chemotherapy demonstrates significant efficacy of nimotuzumab.
【XinSheng Academic】Interim analysis of the Phase III clinical trial evaluating nimotuzumab in combination with concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) officially published